Half-Life Extension of Therapeutic Antibodies

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (10 April 2022) | Viewed by 308

Special Issue Editor

Roche Innovation Center, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Munich, Germany
Interests: therapeutic proteins; antibodies; Fc receptor biology; FcRn; antibody recycling mechanism; mechanism of action; affinity determination technologies; surface plasmon response; affinity column chromatography; protein folding

Special Issue Information

Dear Colleagues,

The number of therapeutic antibodies in clinical development has been continuously increasing over the last several decades. Monoclonal therapeutic antibodies are established as classical immunoglobulin G (IgG)-like scaffolds such as more complex formats with novel functions and differentiated mechanisms of action. IgG1, the most abundant isotype, has the longest half-life amongst the immunoglobulins due to the pH-dependent active FcRn-mediated recycling mechanism. This Special Issue of Antibodies aims to collect original manuscripts and reviews covering the attempts made so far to engineer IgG-based formats for significant half-life extensions, including the research activity that was needed to understand this mechanism in more detail to repair unexpected fast clearance of complex novel IgG-based formats.

Dr. Tilman Schlothauer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • FcRn recycling;
  • half-life extension;
  • complex Fc based formats;
  • modulating clearance

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop